辉瑞SARS-CoV-2 BNT162b2 mRNA疫苗接种(BNT162b2)对择期卵母细胞冷冻保存结局无不良影响
这项在大学附属IVF中心的回顾性队列研究纳入2020年12月至2022年1月间232个择期卵母细胞冷冻保存周期,比较接种疫苗组与疫情前及疫情期间未接种组的结局。接种组获卵数和成熟卵母细胞数与两个未接种组相当,接种后9至13个月仍无不良影响。
要点
- 接种组与疫情前未接种组获卵数12.6±8.0 vs 13.0±8.2、成熟卵母细胞数10.1±6.9 vs 9.5±6.4,均无显著差异。
- 接种组与疫情期间未接种组获卵数12.6±8.0 vs 12.5±7.4、成熟卵母细胞数10.1±6.9 vs 10.1±6.3,均无显著差异。
- 接种后9至13个月的时间间隔内,疫苗接种状态和时机与成熟卵母细胞数无关联。
核心结论
- SARS-CoV-2疫苗接种不改变择期卵母细胞冷冻保存的结局,即使在接种后9至13个月的相对较长时间间隔内也是如此。
研究设计与样本
- 回顾性队列研究,在大学附属IVF中心进行,纳入2020年12月至2022年1月间232个无既往SARS-CoV-2感染的接种和未接种患者的择期卵母细胞冷冻保存周期。
- 设两个对照组:疫情前未接种组(2019年1月至2020年2月)和疫情期间未接种组(2020年12月至2022年1月),并与接种组比较,接种组进一步分为四个亚组(小于3个月、3至6个月、6至9个月和9至13个月)。
- 主要结局为择期卵母细胞冷冻保存周期结局——获卵数和成熟卵母细胞数。
主要发现
- 接种组与疫情前未接种组和疫情期间未接种组相比,获卵数分别为12.6±8.0 vs 13.0±8.2和12.5±7.4,成熟卵母细胞数分别为10.1±6.9 vs 9.5±6.4和10.1±6.3,两者均无显著差异。
- 疫情期间未接种组与四个接种亚组比较也观察到类似结果。
- 接种后天数与周期结局参数之间未发现相关性。
- 协方差分析显示疫苗接种状态和时机与成熟卵母细胞数之间无关联。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RESEARCH QUESTION: Do elective oocyte cryopreservation outcomes in women 1-13 months after SARS-CoV-2 vaccination alter compared with unvaccinated women and do different time intervals between vaccination and ovarian stimulation impact these outcomes? DESIGN: This retrospective cohort study, conducted in a university-affiliated IVF centre, included 232 elective oocyte cryopreservation cycles of vaccinated and unvaccinated patients, without previous infection with the SARS-CoV-2 virus, between December 2020 and January 2022. Two control groups - pre-pandemic (January 2019 to February 2020) and intra-pandemic (December 2020 to January 2022) unvaccinated groups - were compared with the vaccinated group, further divided into four subgroups (under 3, 3-6, 6-9 and 9-13 months). The primary outcome was the elective oocyte cryopreservation cycle outcomes - number of retrieved and number of mature oocytes. RESULTS: The vaccinated group demonstrated comparable outcomes with regards to number of retrieved and mature oocytes compared with the pre-pandemic and intra-pandemic unvaccinated groups (12.6 ± 8.0 versus 13.0 ± 8.2 and 12.5 ± 7.4 retrieved and 10.1 ± 6.9 versus 9.5 ± 6.4 and 10.1 ± 6.3 mature oocytes, respectively; not significant for both). Similar results were noted in a comparison between the intra-pandemic unvaccinated group and the four vaccinated subgroups. No correlation was found between the parameter of days from vaccination and cycle outcomes. Similarly, analysis of covariance showed no association between vaccination status and timing and number of mature oocytes. CONCLUSIONS: The SARS-CoV-2 vaccination does not alter the outcomes of elective oocyte cryopreservation procedures. This is true even in a relatively long time interval of 9 to 13 months from vaccination.
引用
- Karavani G, Chill HH, Dick A, et al. Pfizer SARS-CoV-2 BNT162b2 mRNA vaccination (BNT162b2) has no adverse effect on elective oocyte cryopreservation outcomes. Reprod Biomed Online. 2022. PMID: 35953414. doi:10.1016/j.rbmo.2022.06.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。